Market Overview

Peripheral Arterial Disease (PAD) Drug Development Pipeline Analysis Report 2018 -


The "2018
Peripheral Arterial Disease (PAD) Drug Development Pipeline Analysis
Report- Companies, Drugs, Clinical Trials, Latest Developments in
Peripheral Arterial Disease (PAD) Market"
report has been added
to's offering.

Peripheral Arterial Disease is a condition in which plaque or fatty
deposits build up in the arteries which supply blood to the leg muscles.
It can cause serious implications such as myocardial infarction,
vascular dementia, stroke etc. An estimated 0.2 billion population is
affected worldwide and the market size of Peripheral Arterial Disease
(PAD) is estimated to be around $4.5 billion.

To assist researchers, investors and business development managers, the
publisher has come up with a comprehensive report on Peripheral Arterial
Disease pipeline. The report provides insights into different
therapeutic candidates in preclinical, research, discovery, NDA/IND, pre
registration, phase 1, phase 2, and phase 3 trials. Drugs under
development directly and through combination with other drugs are also

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Peripheral Arterial
Disease (PAD) pipeline product. Mechanism of Action and the target area
of the pipeline product are also provided. Further, clinical and
preclinical trials along with results of the trials are also included in
the report.

Companies Mentioned

  • 480 Biomedical, Inc.
  • Alucent Medical Inc
  • Anaeropharma Science, Inc.
  • AnGes MG Inc
  • AngioSoma Inc
  • apceth Biopharma GmbH
  • Athera Biotechnologies AB
  • Athersys Inc
  • Bayer AG
  • Betagenon AB
  • BiogenCell Ltd
  • CardioVascular BioTherapeutics Inc
  • Celularity Inc
  • Exodos Life Sciences LP
  • Foresee Pharmaceuticals Co Ltd
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • LipimetiX Development Inc
  • MultiGene Vascular Systems (MGVS) Ltd
  • Nangiotx Inc
  • Novartis AG
  • Nuo Therapeutics Inc
  • Pluristem Therapeutics Inc.
  • G. Pohl-Boskamp GmbH & Co. KG
  • Proteon Therapeutics Inc
  • Resverlogix Corporation
  • Reven Pharmaceuticals Inc
  • RHEACELL GmbH & Co. KG
  • SK Chemicals Co.,Ltd
  • Stemedica Cell Technologies Inc
  • Symic Biomedical Inc
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • Yuyu Pharma Inc

Key Topics Covered:

1 Table of Contents

2 Peripheral Arterial Disease (PAD) Pipeline Analysis

3 Peripheral Arterial Disease (PAD)- Company Wise Pipeline Analysis

4 Peripheral Arterial Disease (PAD) R&D Pipeline Snapshots

5 Recent Developments in Peripheral Arterial Disease (PAD) Pipeline

6 Appendix

For more information about this report visit

View Comments and Join the Discussion!